Associated Papers
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Patients with Papillary Renal Cancer and Germline Duplication of MET Exons 5-21.
Mikhaylenko DS et al.
Biomedicines, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR et al.
Clinical and Translational Medicine, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Elife, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Advances in the diagnosis and treatment of MET-variant digestive tract tumors.
Zhang C et al.
World Journal of Gastrointestinal Oncology, 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase.
Yao HP et al.
Therapeutic Advances in Medical Oncology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.
Kim J et al.
Cancers, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J et al.
Frontiers in Oncology, 2020
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2017
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J et al.
Oncotarget, 2017
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE et al.
Molecular Cancer Therapeutics, 2016
The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
Mohyeldin MM et al.
Oncotarget, 2016
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB et al.
Investigational New Drugs, 2013
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL et al.
Biochemistry, 2009
Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
c-Met inhibitors with different binding modes: two is better than one.
Dussault I et al.
Cell Cycle (georgetown, Tex.), 2008
Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
Zhang W et al.
Cancer Genetics, 0